Table 3.

Potential targets for NETs inhibition in different disease

Agent/Inhibitor	Target/Function	Disease/Pathology	Subject of research	Reference
DNase I	Degrading formed NETs	Diabetic wound healing	Diabetic mouse	[120]
		Liver IRI	Liver IRI mouse	[121]
		lung injury/ARDS	MRSA-infected mouse	[122]
		SLE	Serum of SLE patients	[123, 124]
		Scar formation	Mouse model of laminectomy	[67]
		Cystic fibrosis	Cystic fibrosis patients	[125, 126]
		Colorectal cancer	MC38-bearing mouse	[127]
		Hepatocellular carcinoma	Hepa1-6 or HuH7 bearing mouse	[43, 128]
		Breast cancer	SCP28-bearing mouse	[129]
		Pancreatic cancer	Panc02-bearing mouse	[19]
rhDNase I	Degrading formed NETs	COVID-19 Infection	Patients in Phase I clinical trial	NCT04409925
GSK484	Inhibitor of PAD4	Renal IRI	Renal IRI mouse	[130]
		Lung injury	SAH mouse	[131]
		Hepatocellular carcinoma	Hepa1-6 bearing mouse	[132]
		Breast cancer	4T1-bearing mice	[28, 129]
Cl-amidine	Inhibitor of PAD4	Mastitis	LPS-induced mouse mastitis	[133]
		Endometritis	LPS-induced rat endometritis	[134]
BMS-P5	Inhibitor of PAD4	Multiple myeloma	DP42-bearing mouse	[135]
Sivelestat	Inhibitor of NE	Ovarian cancer	Human neutrophils	[136]
		Breast cancer	SCP28-bearing mouse	[129]
GW311616	Inhibitor of NE	Diffuse large B-cell lymphoma	A20-bearing mouse	[21]
		Inflammatory responses	Human neutrophils	[137]
AZD5904	Inhibitor of MPO	Multiple organ dysfunction in sepsis	Human neutrophils	[138]
Reparixin	CXCR1/2 inhibitor	solid malignancies	Tumor-bearing mice	[28]
Danirixin	CXCR2 antagonist	COPD	Patients in Phase II clinical trial	NCT03250689
Metformin	Inhibiting NADPH oxidase activity	SLE	Proof-of-Concept Trial	[139]